2-oxo-4,3a-dihydroimidazolidino[2,1-b]quinazolin-6-yl acetic acid | 721966-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-oxo-4,3a-dihydroimidazolidino[2,1-b]quinazolin-6-yl acetic acid
• 英文别名: 2-oxo-4,3a-dihydroimidazolidino[2,1-b]quinazolin-6-yl acetate；(2-oxo-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-7-yl) acetate
• CAS: 721966-78-5
• 化学式: C₁₂H₁₁N₃O₃
• 分子量: 245.238
• InChiKey: UNZNMILTFFQDBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  71
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-oxo-4,3a-dihydroimidazolidino[2,1-b]quinazolin-6-yl acetic acid 生成 7-hydroxy-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one
  参考文献：
  名称：

  [EN] DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY
  [FR] COMPOSES DE DIHYDROPYRIDINE PRESENTANT A LA FOIS LA CAPACITE DE BLOQUER DES CANAUX CALCIQUES DE TYPE L ET LA CAPACITE D'INHIBER L'ACTIVITE DE TYPE 3 DE LA PHOSPHODIESTERASE

  摘要：

  本发明提供了具有对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。

  公开号：

  WO2004033444A1
• 作为产物：
  描述：

  在 palladium 10% on activated carbon 氢气 、 溴化氰 、 三乙胺 作用下， 以 乙醇 为溶剂， 生成 2-oxo-4,3a-dihydroimidazolidino[2,1-b]quinazolin-6-yl acetic acid
  参考文献：
  名称：

  [EN] COMPOUNDS WITH MIXED PDE-INHIBITORY AND beta-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
  [FR] COMPOSES PRESENTANT UNE ACTIVITE MIXTE D'INHIBITION DE LA PDE ET D'ANTAGONISTE OU D'AGONISTE PARTIEL 20041125EP0116948A2SYNTEX INC [US]198408291,27-29A1,25,37,40AEP0355583A2OTSUKA PHARMA CO LTD [JP]1990022872121X37XGB2190676ABRISTOL MYERS CO1987112510521165143X1,25,37XGB1465946ACIBA GEIGY AG19770302411311,23,12428mX1,25,37XEP0029992A1BOEHRINGER MANNHEIM GMBH [DE]198106101,92g,6hX1,25,37XDE2950479A1NATTERMANN A & CIE [DE]19810619811,32,3X1,25,37XUS5641783AKLEIN J PETER [US], et al19970624claims 1, 18 (column 97, line 5) and 21X1,25XGB1488330ASMITH KLINE FRENCH LAB19771012page 3, lines 32-37 and page 4, lines 1-16; claim 1X25,37XEP0138344A2SMITH KLINE FRENCH LAB [GB]19850424page 6, line 13- page 7, line 25X25,37XGB1567907ASMITH KLINE FRENCH LAB19800521page 5, lines 22-23; page 6, lines 51-52;X1XEGUCHI, YUKUO ET AL: "Studies on antiatherosclerotic agents. Synthesis of 7-ethoxycarbonyl-4-formyl-6,8-dimethyl-1(2H)-phthalazinone derivatives and related compounds", CHEMICAL & PHARMACEUTICAL BULLETIN , 39(3), 795-7 CODEN: CPBTAL; ISSN: 0009-2363, 1991, XP001194680EGUCHI, YUKUO ET ALStudies on antiatherosclerotic agents. Synthesis of 7-ethoxycarbonyl-4-formyl-6,8-dimethyl-1(2H)-phthalazinone derivatives and related compoundsCHEMICAL & PHARMACEUTICAL BULLETIN , 39(3), 795-7 CODEN: CPBTAL; ISSN: 0009-23631991compound 10 and table IX1,25,37XM.S. CHODNEKAR ET AL.: "Beta-Adrenergic blocking agents. 11. Heterocyclic analogs of pronethalol[2-isopropylamino-1-(2-naphthyl)ethanol]", JOURNAL OF MEDICINAL CHEMISTRY., vol. 15, no. 1, 1972, USAMERICAN CHEMICAL SOCIETY. WASHINGTON., pages 49 - 57, XP002292174M.S. CHODNEKAR ET AL.Beta-Adrenergic blocking agents. 11. Heterocyclic analogs of pronethalol[2-isopropylamino-1-(2-naphthyl)ethanol]JOURNAL OF MEDICINAL CHEMISTRY.USAMERICAN CHEMICAL SOCIETY. WASHINGTON.19721514957compound 30X37XGB1540628AOTSUKA PHARMA CO LTD197902141,83page 1, lines 6-24; examplesX1,25,37XCROWTHER A F ET AL: "BETA-ADRENERGIC BLOCKING AGENTS. 12. HETEROCYCLIC COMPOUNDS RELATEDTO PROPRANOLOL", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 15, no. 3, 1972, pages 260 - 266, XP000909966, ISSN: 0022-2623CROWTHER A F ET ALBETA-ADRENERGIC BLOCKING AGENTS. 12. HETEROCYCLIC COMPOUNDS RELATEDTO PROPRANOLOLJOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US19721530022-2623260266VIIX37XDATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKAGAWA, KAZUYUKI ET AL: "Carbostyril derivatives", XP002292176, retrieved from STN Database accession no. 1977:453098NAKAGAWA, KAZUYUKI ET ALCarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1977:453098STNAabstract and compounds 61122-74-5, 61122-75-6, 63423-80-3, 63423-81-4X1,25,37XJPS51125291AOTSUKA PHARMA CO LTD19761101DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKAGAWA, KAZUYUKI ET AL: "Carbostyril derivatives", XP002292177, retrieved from STN Database accession no. 1977:89632NAKAGAWA, KAZUYUKI ET ALCarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1977:89632STNAabstract and compounds 61122-74-5 and 61122-75-6X1,25,37XJPS5168575AOTSUKA PHARMA CO LTD19760614DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ISHIKAWA, HIROSHI ET AL: "Carbostyril derivatives", XP002292178, retrieved from STN Database accession no. 1978:509144ISHIKAWA, HIROSHI ET ALCarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1978:509144STNAcompound 67358-84-3X1,25,37XJPS5350182AOTSUKA PHARMA CO LTD19780508DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SAKANO, KAZUHISA ET AL: "3,4-Dihydrocarbostyril derivatives", XP002292179, retrieved from STN Database accession no. 1979:405123SAKANO, KAZUHISA ET AL3,4-Dihydrocarbostyril derivativesCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1979:405123STNAcompounds 70386-53-7, 70386-41-3, 63423-80-3X1,25,37XJPS5416478AOTSUKA PHARMA CO LTD19790207DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; "Carbostyrils", XP002292180, retrieved from STN Database accession no. 1982:406175CarbostyrilsCHEMABSCHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US1982:406175STNAcompound 81994-29-8X1,25XJPS5742673AOTSUKA PHARMA CO LTD19820310WO8402908A1POS LAB [FR]1984080213191,4X1,25,37XKIKKAWA, HIDEO ET AL: "The role of the seventh transmembrane region in high affinity binding of a .beta.2-selective agonist TA-2005", MOLECULAR PHARMACOLOGY , 53(1), 128-134 CODEN: MOPMA3; ISSN: 0026-895X, 1998, XP001199449KIKKAWA, HIDEO ET ALThe role of the seventh transmembrane region in high affinity binding of a .beta.2-selective agonist TA-2005MOLECULAR PHARMACOLOGY , 53(1), 128-134 CODEN: MOPMA3; ISSN: 0026-895X1998compounds II and III; abstractX1,25,37XDEYRUP, M. D. ET AL: "Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the .beta.2-adrenoceptor", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY , 359(3), 168-177 CODEN: NSAPCC; ISSN: 0028-1298, 1999, XP001199515DEYRUP, M. D. ET ALStructure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the .beta.2-adrenoceptorNAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY , 359(3), 168-177 CODEN: NSAPCC; ISSN: 0028-12981999compounds 10b, 10c, 10gX1,25,37XWO03015785A1ICOS CORP [US], et al20030227page 51, line 1, column 3PX1,25PXSIVAKUMAR, RAMAIYA ET AL: "Pharmacological evaluation of some new 1-substituted-4-hydroxy- phthalazines", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 37(10), 793-801 CODEN: EJMCA5; ISSN: 0223-5234, 2002, XP004393912SIVAKUMAR, RAMAIYA ET ALPharmacological evaluation of some new 1-substituted-4-hydroxy- phthalazinesEUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 37(10), 793-801 CODEN: EJMCA5; ISSN: 0223-52342002compounds 5, 7 and 12 and table 1PX1,25PX

  摘要：

  公开号：

  WO2004050657A3

文献信息

• Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
  申请人：Hamilton Gregory

  公开号：US20070117978A1

  公开（公告）日：2007-05-24

  The present invention provides compounds possessing inhibitory activity against (3-adrenergic receptors and phosphodiesterase (PDE), including type 3 phosphodiesterase (PDE-3). The present invention further provides pharmaceutical compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for regulating calcium homeostasis, for treating a disease, disorder or condition in which disregulation of calcium homeostasis is implicated and for treating cardiovascular disease, stroke, epilepsy, an ophthalmic disorder or migraine.

  本发明提供了具有抑制(3-肾上腺素受体和磷酸二酯酶(PDE)活性的化合物，包括3型磷酸二酯酶(PDE-3)。本发明还提供了包含这些化合物的制药组合物，制备这些化合物的方法，以及使用这些化合物调节钙离子稳态，治疗涉及钙离子稳态失调的疾病、紊乱或状况，以及治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
• Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
  申请人：Hamilton S. Gregory

  公开号：US20070060748A1

  公开（公告）日：2007-03-15

  This invention provides compounds that possess inhibitory activity against β-adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against β-adrenergic receptors and PDE.

  本发明提供了一种具有对β-肾上腺素能受体和磷酸二酯酶PDE，包括磷酸二酯酶3（PDE3）的抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物；使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法；以及制备具有对β-肾上腺素能受体和PDE抑制活性的药物组合物和化合物的方法。
• Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
  申请人：Hamilton S. Gregory

  公开号：US20070066619A1

  公开（公告）日：2007-03-22

  The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.

  本发明提供了具有对 PDE-3 和 L 型钙通道抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
• [EN] CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST beta-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE<br/>[FR] COMPOSES CARDIOTONIQUES A ACTIVITE INHIBITRICE SUR LES RECEPTEURS ADRENERGIQUES DOLLAR G(B) ET LA PHOSPHODIESTERASE
  申请人：ARTESIAN THERAPEUTICS INC

  公开号：WO2004058726A3

  公开（公告）日：2004-10-28
• [EN] COMPOUNDS WITH MIXED PDE-INHIBITORY AND beta-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE<br/>[FR] COMPOSES PRESENTANT UNE ACTIVITE MIXTE D'INHIBITION DE LA PDE ET D'ANTAGONISTE OU D'AGONISTE PARTIEL 20040617
  申请人：ARTESIAN THERAPEUTICS INC

  公开号：WO2004050657A2

  公开（公告）日：2004-06-17

  This invention provides compounds that possess inhibitory activity against β-­adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3 ). This invention further provides pharmaceutical compositions comprising such ­compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against ß-adrenergic receptors and PDE.